Charles Schwab’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $241M | Sell |
1,117,663
-31,731
| -3% | -$6.07M | 0.03% | 400 |
|
|
2026
Q1 | $211M | Buy |
1,149,394
+5,492
| +0.5% | +$1.01M | 0.03% | 401 |
|
|
2025
Q4 | $201M | Buy |
1,143,902
+20,553
| +2% | +$3.36M | 0.03% | 407 |
|
|
2025
Q3 | $157M | Buy |
1,123,349
+47,592
| +4% | +$6.43M | 0.03% | 489 |
|
|
2025
Q2 | $135M | Buy |
1,075,757
+56,538
| +6% | +$7.04M | 0.02% | 538 |
|
|
2025
Q1 | $139M | Buy |
1,019,219
+47,956
| +5% | +$6.86M | 0.03% | 498 |
|
|
2024
Q4 | $149M | Buy |
971,263
+58,234
| +6% | +$9.82M | 0.03% | 476 |
|
|
2024
Q3 | $177M | Buy |
913,029
+12,319
| +1% | +$2.58M | 0.03% | 409 |
|
|
2024
Q2 | $209M | Buy |
900,710
+41,905
| +5% | +$9.11M | 0.04% | 372 |
|
|
2024
Q1 | $185M | Buy |
858,805
+9,805
| +1% | +$2.3M | 0.04% | 375 |
|
|
2023
Q4 | $220M | Buy |
849,000
+310
| +0% | +$76.1K | 0.06% | 302 |
|
|
2023
Q3 | $218M | Sell |
848,690
-1,511
| -0.2% | -$404K | 0.06% | 277 |
|
|
2023
Q2 | $242M | Buy |
850,201
+5,819
| +0.7% | +$1.73M | 0.07% | 239 |
|
|
2023
Q1 | $235M | Buy |
844,382
+8,088
| +1% | +$2.24M | 0.07% | 242 |
|
|
2022
Q4 | $232M | Buy |
836,294
+15,726
| +2% | +$4.44M | 0.07% | 242 |
|
|
2022
Q3 | $219M | Buy |
820,568
+30,684
| +4% | +$6.52M | 0.08% | 230 |
|
|
2022
Q2 | $161M | Buy |
789,884
+25,124
| +3% | +$5.14M | 0.06% | 309 |
|
|
2022
Q1 | $161M | Buy |
764,760
+23,023
| +3% | +$5.01M | 0.05% | 349 |
|
|
2021
Q4 | $178M | Buy |
741,737
+10,539
| +1% | +$2.71M | 0.05% | 333 |
|
|
2021
Q3 | $207M | Buy |
731,198
+7,369
| +1% | +$2.42M | 0.07% | 258 |
|
|
2021
Q2 | $251M | Buy |
723,829
+19,565
| +3% | +$5.93M | 0.08% | 209 |
|
|
2021
Q1 | $197M | Sell |
704,264
-6,138
| -0.9% | -$1.66M | 0.07% | 243 |
|
|
2020
Q4 | $174M | Sell |
710,402
-24,678
| -3% | -$6.37M | 0.07% | 259 |
|
|
2020
Q3 | $209M | Sell |
735,080
-90,630
| -11% | -$25.3M | 0.1% | 192 |
|
|
2020
Q2 | $221M | Sell |
825,710
-112,088
| -12% | -$33.7M | 0.11% | 178 |
|
|
2020
Q1 | $297M | Buy |
937,798
+3,467
| +0.4% | +$1.05M | 0.17% | 111 |
|
|
2019
Q4 | $277M | Sell |
934,331
-33,539
| -3% | -$9.31M | 0.15% | 122 |
|
|
2019
Q3 | $225M | Buy |
967,870
+36,633
| +4% | +$8.53M | 0.13% | 144 |
|
|
2019
Q2 | $218M | Buy |
931,237
+14,919
| +2% | +$3.44M | 0.13% | 142 |
|
|
2019
Q1 | $217M | Buy |
916,318
+6,944
| +0.8% | +$2.19M | 0.14% | 133 |
|
|
2018
Q4 | $274M | Buy |
909,374
+21,321
| +2% | +$6.8M | 0.21% | 87 |
|
|
2018
Q3 | $314M | Sell |
888,053
-32,534
| -4% | -$11.2M | 0.21% | 81 |
|
|
2018
Q2 | $267M | Buy |
920,587
+28,440
| +3% | +$8M | 0.19% | 87 |
|
|
2018
Q1 | $244M | Buy |
892,147
+59,509
| +7% | +$18.5M | 0.19% | 92 |
|
|
2017
Q4 | $265M | Buy |
832,638
+56,333
| +7% | +$18.1M | 0.21% | 82 |
|
|
2017
Q3 | $243M | Sell |
776,305
-22,164
| -3% | -$6.56M | 0.21% | 79 |
|
|
2017
Q2 | $217M | Sell |
798,469
-41,171
| -5% | -$10.9M | 0.2% | 89 |
|
|
2017
Q1 | $230M | Buy |
839,640
+60,754
| +8% | +$17.2M | 0.23% | 76 |
|
|
2016
Q4 | $221M | Buy |
778,886
+33,444
| +4% | +$9.91M | 0.24% | 69 |
|
|
2016
Q3 | $233M | Buy |
745,442
+96,902
| +15% | +$28.7M | 0.27% | 60 |
|
|
2016
Q2 | $157M | Buy |
648,540
+14,973
| +2% | +$3.95M | 0.2% | 96 |
|
|
2016
Q1 | $165M | Sell |
633,567
-4,293
| -0.7% | -$1.13M | 0.22% | 82 |
|
|
2015
Q4 | $195M | Sell |
637,860
-23,873
| -4% | -$6.86M | 0.26% | 72 |
|
|
2015
Q3 | $193M | Sell |
661,733
-45,829
| -6% | -$15.1M | 0.28% | 64 |
|
|
2015
Q2 | $286M | Buy |
707,562
+12,205
| +2% | +$4.9M | 0.39% | 48 |
|
|
2015
Q1 | $294M | Buy |
695,357
+33,022
| +5% | +$13M | 0.41% | 46 |
|
|
2014
Q4 | $225M | Buy |
662,335
+15,009
| +2% | +$4.86M | 0.34% | 53 |
|
|
2014
Q3 | $214M | Buy |
647,326
+36,029
| +6% | +$11.9M | 0.35% | 50 |
|
|
2014
Q2 | $193M | Sell |
611,297
-11,641
| -2% | -$3.5M | 0.32% | 57 |
|
|
2014
Q1 | $191M | Buy |
622,938
+23,423
| +4% | +$7.44M | 0.34% | 53 |
|
|
2013
Q4 | $168M | Buy |
599,515
+18,203
| +3% | +$4.71M | 0.32% | 59 |
|
|
2013
Q3 | $142M | Buy |
581,312
+71,066
| +14% | +$15.9M | 0.29% | 69 |
|
|
2013
Q2 | $111M | Buy |
+510,246
| New | +$109M | 0.25% | 81 |
|
Other funds holding BIIB
Charles Schwab's BIIB Position: Q2 2026 in Review
Charles Schwab reduced its Biogen (BIIB) stake by 2.8% in Q2 2026, selling an estimated $6.07M and leaving 1,117,663 shares worth $241M. The position accounts for 0.03% of the portfolio, ranked #400.
Charles Schwab first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $314M in Q3 2018. 1,038 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Charles Schwab held 1,117,663 shares of Biogen worth $241M as of Q2 2026.
- Charles Schwab sold 31,731 Biogen shares in Q2 2026, an estimated $6.07M.
- Biogen made up 0.03% of Charles Schwab's portfolio in Q2 2026, its #400 holding.
- Charles Schwab first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's Biogen position peaked at $314M in Q3 2018.
- 1,038 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.